According to Sihuan Biotech's announcement, net profit attributable to shareholders of listed companies from January 1, 2026 to June 30, 2026 is expected to be -30 million yuan to 21 million yuan, a year-on-year decrease of 107.94%-197.06%; net profit after deducting non-recurring profit and loss is -34 million yuan to -24 million yuan, a year-on-year decrease of 100.68%-184.30%. During the reporting period, the holding subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd., was affected by the interprovincial alliance's centralized drug procurement policy, and sales prices of the main winning products declined, leading to a year-on-year decline in operating income and a year-on-year increase in losses.

According to Sihuan Biotech's announcement, net profit attributable to shareholders of listed companies from January 1, 2026 to June 30, 2026 is expected to be -30 million yuan to 21 million yuan, a year-on-year decrease of 107.94%-197.06%; net profit after deducting non-recurring profit and loss is -34 million yuan to -24 million yuan, a year-on-year decrease of 100.68%-184.30%. During the reporting period, the holding subsidiary, Beijing Sihuan Biopharmaceutical Co., Ltd., was affected by the interprovincial alliance's centralized drug procurement policy, and sales prices of the main winning products declined, leading to a year-on-year decline in operating income and a year-on-year increase in losses.